Clive Harmer – författare

Written by a multidisciplinary team of experts involved in the development of standards and guidelines for its management in the USA, UK, Europe and Asia, the book contains succinct and knowledgeable summaries of the management of thyroid cancer. Every chapter describes a different aspect of care, and provides clear and detailed information about caring for patients with this group of tumors. The book follows the American and European model of treating thyroid cancer according to the high standards recommended by the available guidelines. This is an invaluable reference to health care professionals, from primary to tertiary care, involved in the management of thyroid cancer such as clinical nurse specialists, clinical psychologists, family medicine practitioners, specialists in palliative care (especially for anaplastic thyroid cancers), geneticists and surgeons, endocrinologists, oncologists, pathologists, and radiologists.

The new edition of this book highlights the recent advances and state-of-the art in surgical and non-surgical management of thyroid cancer. Readers will learn about the latest advances and recommendations in the field, from molecular studies and biomarkers to the changing epidemiology, kinase inhibition in drug discovery and new surgical approaches, such as intra-operative neural monitoring and robotics. The management of differentiated thyroid cancer as well as childhood cancer, survivorship and clinical trial design and findings and how these fit into cancer management are discussed in detail.This comprehensive volume provides an overview of the current world literature and outlines the practical aspects of management from world leaders in this field and helps clinicians and patients on practical matters. With a selection of authors from around the world it draws on international experience giving a global perspective to the topic. Following on from the success of the firstedition, it uses a multidisciplinary, evidence-based approach centered on the patient, discussing guidelines and how these have improved the quality of care and outcomes. This guide is aimed mainly at thyroidologists of all disciplines, (in training or experts) students, non-specialist clinicians, nursing staff, all the disciplines involved in a multidisciplinary team such as surgeons – Head & Neck or Endocrine and General Surgeons,  Oncologists, Endocrinologists, Nuclear Medicine Physicians, Nuclear Medicine Physicists, Radiologists, Pathologists, Specialist  Nurses, Geneticists, Clinical Psychologists, Palliative Care Physicians and, of course, patients.

Written by leading world experts, this third edition embraces the philosophy of international collaboration and disseminates the latest advances and transformative changes in the field of thyroid cancer.It provides a global health perspective, striving towards a uniform, equitable, evidence-based, cost-effective, practical, and patient-centred approach with high quality care crossing geographical boundaries. This book covers controversial issues and the most up-to-date management of differentiated, medullary, anaplastic, and rarer types of thyroid cancers together with survivorship issues and the lessons learnt during the Covid-19 Pandemic.The molecular landscape of thyroid cancers has a high frequency of oncogenic driver mutations and a high frequency of gene fusions treatable by new gene-specific systemic therapies. These include dual MAPK (Dabrafenib) / MEK (Trametinib) inhibition in BRAF V 600E mutated Anaplastic Thyroid Cancer, Larotrectinib, Entrectinib for NTRKgene fusion, Selpercartinib, Pralsetinib for RET fusion and mutations. These, newer and Master protocol trials, Tumour Agnostic drug development, Immune Checkpoint blockade and CAR-T therapy etc are discussed.The latest NICE and African Guidelines for Management are included. This would be of interest to readers as well.This book is aimed at thyroidologists of all disciplines, (in training or experts) students, non-specialist clinicians, nursing staff, all the disciplines involved in a multidisciplinary team such as surgeons - Head & Neck or Endocrine and General Surgeons, Oncologists, Endocrinologists, Nuclear Medicine Physicians, Nuclear Medicine Physicists, Radiologists, Pathologists, Specialist Nurses, Geneticists, Clinical Psychologists, Palliative Care Physicians and, in addition to AI in medicine, telemedicine experts, health policy makers, and scientists.